AMPICILLIN FOR INJECTION, USP POWDER FOR SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

AMPICILLIN (AMPICILLIN SODIUM)

Pieejams no:

STERIMAX INC

ATĶ kods:

J01CA01

SNN (starptautisko nepatentēto nosaukumu):

AMPICILLIN

Deva:

250MG

Zāļu forma:

POWDER FOR SOLUTION

Kompozīcija:

AMPICILLIN (AMPICILLIN SODIUM) 250MG

Ievadīšanas:

INTRAMUSCULAR

Vienības iepakojumā:

2ML(125MG/ML)

Receptes veids:

Prescription

Ārstniecības joma:

AMINOPENICILLINS

Produktu pārskats:

Active ingredient group (AIG) number: 0105872002; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2015-06-17

Produkta apraksts

STERI
_MAX _
INC.
_ _
_ _
AMPICILLIN FOR INJECTION, USP_ _
PRESCRIBING INFORMATION
PR
AMPICILLIN FOR INJECTION, USP
250 mg, 500 mg, 1,000 mg, 2,000 mg, and 10,000 mg per vial
ampicillin (as ampicillin sodium)
Sterile
Antibiotic
STERIMAX INC.
DATE OF REVISION:
2770 Portland Drive,
September 24, 2019
Oakville, ON
L6H 6R4
CONTROL #: 223928
STERI
_MAX _
INC.
_ _
_ _
AMPICILLIN FOR INJECTION, USP_ _
Page 2 of 12
PR
AMPICILLIN FOR INJECTION, USP
ANTIBIOTIC
ACTIONS AND CLINICAL PHARMACOLOGY:
Ampicillin has a broad spectrum of bactericidal activity against many
gram-positive and
gram-negative aerobic and anaerobic bacteria. It acts through the
inhibition of cell wall
mucopeptide biosynthesis during the stage of active multiplication.
INDICATIONS AND CLINICAL USE:
The treatment of infections due to susceptible gram negative organisms
(including strains of
shigellae, _S. typhosa _and other salmonellae, _E. coli, H.
influenzae, _and _P. mirabilis_) and
susceptible gram positive organisms (including streptococci,
pneumococci,_ _and non-beta-
lactamase (penicillinase) producing staphylococci). Infections of the
ear, nose, throat and
lower respiratory tract.
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of
AMPICILLIN FOR INJECTION, USP and other antibacterial drugs,
AMPICILLIN FOR INJECTION,
USP should be used only to treat infections that are proven or
strongly suspected to be
caused by susceptible bacteria. When culture and susceptibility
information are available,
they should be considered in selecting or modifying antibacterial
therapy. In the absence of
such data, local epidemiology and susceptibility patterns may
contribute to the empiric
selection of therapy.
CONTRAINDICATIONS:
A history of allergic reactions to penicillin or cephalosporins.
WARNINGS:
Before therapy, inquiry as to past penicillin or other allergies is
essential as reactions occur
more frequently in hypersensitive persons. During therapy, if allergic
or anaphylactic
reactions occur, discontinue treatment and initiate